April 29, 2010 — This drug is for patients with metastatic or prostate cancer that has spread outside the prostate ( this is uncommon condition ) There are no great treatments for these patients but this therapy may help!
click on drug name to see full article from new york times today…
In a widely anticipated announcement, the US Food and Drug Administration (FDA) has approved an immunotherapy, sipuleucel-T (Provenge, Dendreon), for the treatment of asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer (mCRPC).
